Nordea Investment Management AB Has $35.93 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Nordea Investment Management AB raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,784 shares of the company’s stock after purchasing an additional 1,166 shares during the period. Nordea Investment Management AB owned 0.23% of Medpace worth $35,930,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in MEDP. Occidental Asset Management LLC bought a new position in shares of Medpace during the 4th quarter worth about $279,000. CWA Asset Management Group LLC increased its position in Medpace by 119.0% in the 4th quarter. CWA Asset Management Group LLC now owns 2,827 shares of the company’s stock valued at $1,588,000 after buying an additional 1,536 shares in the last quarter. Riversedge Advisors LLC raised its stake in Medpace by 31.0% during the 4th quarter. Riversedge Advisors LLC now owns 558 shares of the company’s stock worth $313,000 after buying an additional 132 shares during the period. GAMMA Investing LLC raised its stake in Medpace by 16.7% during the 4th quarter. GAMMA Investing LLC now owns 872 shares of the company’s stock worth $490,000 after buying an additional 125 shares during the period. Finally, IFP Advisors Inc boosted its holdings in Medpace by 157.2% in the third quarter. IFP Advisors Inc now owns 499 shares of the company’s stock worth $257,000 after acquiring an additional 305 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. Royal Bank Of Canada began coverage on Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective for the company. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a report on Tuesday, February 10th. Mizuho set a $582.00 price target on shares of Medpace in a research report on Wednesday, February 11th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a research note on Friday, February 13th. Finally, Leerink Partners lowered their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Trading Up 1.0%

Shares of NASDAQ:MEDP opened at $456.93 on Tuesday. The stock has a market cap of $12.97 billion, a PE ratio of 29.86, a price-to-earnings-growth ratio of 2.17 and a beta of 1.44. The stock’s fifty day simple moving average is $506.24 and its two-hundred day simple moving average is $538.51. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the company posted $3.67 earnings per share. The firm’s revenue for the quarter was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.